ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM Apr 10, 2025 04:00PM
ROSEN, A LEADING AND RANKED FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM Apr 7, 2025 06:13PM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM Apr 5, 2025 03:15PM
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM Apr 4, 2025 03:10PM
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM Apr 2, 2025 02:15PM
View Older Stories

Apr 1, 2025 12:35PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
Mar 24, 2021 08:00AM Anthem (ANTM) to Acquire myNEXUS
Mar 24, 2021 08:00AM Anthem, Inc. To Acquire myNEXUS, Home Health Benefits Manager
Feb 5, 2020 08:03AM Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
Apr 8, 2019 08:00AM Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
Apr 3, 2019 08:00AM Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR
Mar 29, 2019 08:00AM Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
Mar 26, 2019 08:00AM Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope
Mar 20, 2019 08:00AM Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
Mar 19, 2019 05:05PM Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
Mar 19, 2019 05:00PM Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
Mar 15, 2019 05:05PM Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings
Mar 15, 2019 08:00AM Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference
Feb 25, 2019 08:07AM Actinium Pharma (ATNM) Says Late Breaking Oral Presentation at TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients
Feb 25, 2019 08:00AM Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
Feb 21, 2019 08:00AM Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
Feb 12, 2019 08:00AM Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
Feb 6, 2019 08:00AM Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program
Feb 5, 2019 08:00AM Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax
Feb 4, 2019 08:06AM Actinium Pharma (ATNM) Commences Second Dosing Cohort of Novel Combination Trial with Actimab-A & CLAG-M Salvage Regimen at Medical College of Wisconsin
Feb 4, 2019 08:00AM Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin
Jan 29, 2019 08:00AM Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th
Jan 25, 2019 08:00AM Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference
Jan 23, 2019 08:00AM Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Jan 17, 2019 08:00AM Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated
Jan 16, 2019 08:00AM Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation C
Jan 3, 2019 08:00AM Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco
Dec 4, 2018 08:01AM Actinium Pharma (ATNM) Announces Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial
Dec 4, 2018 08:00AM Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
Dec 3, 2018 08:04AM Actinium Pharma (ATNM) Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH
Dec 3, 2018 08:00AM Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate
Nov 19, 2018 08:00AM Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
Nov 5, 2018 08:00AM Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference
Nov 1, 2018 09:01AM Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data
Oct 30, 2018 05:05PM Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax
Oct 26, 2018 08:00AM Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update
Oct 24, 2018 08:00AM Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference
Oct 22, 2018 08:09AM Actinium Pharma (ATNM) Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update
Oct 22, 2018 08:04AM Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update
Oct 1, 2018 08:00AM Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers
Sep 26, 2018 08:00AM Actinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T
Sep 20, 2018 08:00AM Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease
Sep 18, 2018 08:00AM Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space
Sep 6, 2018 08:00AM Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
Sep 4, 2018 08:00AM Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions
Aug 14, 2018 05:43PM Actinium Pharma (ATNM) to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive DMC Meeting
Aug 14, 2018 04:05PM Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
Jul 17, 2018 05:30PM Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning
Jul 9, 2018 04:15PM Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients
Jun 28, 2018 08:09AM Actinium Pharma (ATNM) Reports New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
View Older Stories